MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Charts
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
AXGN stock logo

AXGN

AxoGen, Inc.

$51.58
1.65
 (3.3%)
Exchange:  NASDAQ
Market Cap:  2.773B
Shares Outstanding:  2.778M
Delayed data
Calculate AXGN Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  Michael D. Dale
Full Time Employees:  622
Address: 
13631 Progress Boulevard
Alachua
FL
32615
US
Website:  https://www.axogeninc.com
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin’s surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen’s market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company’s main operations are situated in Alachua, Florida.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/07/29 — Q2 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue159,012187,338225,208
Gross Profit121,869141,977167,353
EBITDA-13,3286,079192
Operating Income-21,462-3,287-7,849
Net Income-21,716-9,964-15,703

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets196,827203,728221,687
Total Liabilities101,16299,82192,840
Total Stockholders Equity95,665103,907128,847
Total Debt69,29268,68619,242
Cash and Cash Equivalents31,02427,55435,548

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-5,7164,535812
Capital Expenditure-14,918-4,524-3,745
Free Cash Flow-20,63411-2,933
Net Income-21,716-9,964-15,703
Net Change in Cash15,491-3,4725,994

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)567,772.663Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)591,621.819Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)579,200Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)-45,423.393Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)-43,592.308Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)-44,469.673Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)57,432.511Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)60,587.875Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)58,944.341Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)412,526.437Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)429,854.512Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)420,829.194Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)1.280Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)1.320Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)1.250Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)2Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)1Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
187.338M  ?P/S
 (TTM)
: 
10.79
?Net Income
 (TTM)
: 
-9964000  ?P/E
 (TTM)
: 
-74.69
?Enterprise Value
 (TTM)
: 
2.635B  ?EV/FCF
 (TTM)
: 
1043.18
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
-17.88%  ?ROIC
 (TTM)
: 
-4.65%
?Net Debt
 (TTM)
: 
29.204M  ?Debt/Equity
 (TTM)
: 
0.08
?P/B
 (TTM)
: 
10.49  ?Current Ratio
 (TTM)
: 
6.6

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
117.23Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about AXGN valuation

Is AxoGen, Inc. (AXGN) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for AxoGen, Inc. (AXGN) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is AXGN a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether AXGN trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is AXGN’s P/E ratio?

You can see AXGN’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for AXGN?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is AXGN a good long-term investment?

Whether AXGN fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

AXGN

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

3.3
MARKETSnap

Trading Metrics:

Open: 50.04   Previous Close: 49.93
Day Low: 49.25   Day High: 51.99
Year Low: 15.24   Year High: 51.99
Price Avg 50: 44.43   Price Avg 200: 36.64
Volume: 845532   Average Volume: 1.205M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel
03-08-2026 02:37
Axogen: The Regulatory Moat Is Becoming A Commercial Flywheel
AxoGen Q2 Earnings Call Highlights
29-07-2026 10:05
AxoGen Q2 Earnings Call Highlights
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
13-05-2026 18:00
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
28-04-2026 17:41
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
AxoGen (AXGN) Q1 Earnings Lag Estimates
28-04-2026 09:16
AxoGen (AXGN) Q1 Earnings Lag Estimates

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Philosophy
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlist & Portfolio Watchlist & Portfolio
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read